Exelixis reported $18.8B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Agios Pharmaceuticals USD 1.61B 598M Nov/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 247.94B 20.06B Nov/2026
AstraZeneca USD 213.88B 23.43B Nov/2026
Bayer EUR 52.42B 5.31B Nov/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Cytokinetics USD 7.51B 1.66B Nov/2026
Eisai JPY 1.49T 73.62B Nov/2026
Eli Lilly USD 1.09T 40.33B Sep/2026
Exelixis USD 19.82B 5.34B Nov/2026
Genmab DKK 17.1B 88.06B Jun/2026
Glaxosmithkline GBP 101.7B 4.58B Nov/2026
Incyte USD 24.6B 1.95B Sep/2026
Ionis Pharmaceuticals USD 4.24B 3.18B Nov/2026
MacroGenics USD 151M 143M Nov/2026
Merck USD 375.59B 17.09B Nov/2026
Moderna USD 99.14B 22.26B Nov/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Novartis USD 292.09B 51.5B Sep/2026
Pfizer USD 165.12B 1.71B Nov/2026
Sanofi EUR 114.34B 15.65B Nov/2026
Takeda JPY 9.26T 1.06T Sep/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Xencor USD 2.14B 281M Nov/2026